Raymond James Begins Coverage on Ginkgo Bioworks (NYSE:DNA)

Raymond James started coverage on shares of Ginkgo Bioworks (NYSE:DNA) in a report published on Wednesday morning, Price Targets.com reports. The firm issued an outperform rating and a $14.50 target price on the stock.

DNA has been the subject of a number of other research reports. William Blair began coverage on shares of Ginkgo Bioworks in a research note on Tuesday. They set an outperform rating for the company. HSBC initiated coverage on shares of Ginkgo Bioworks in a research note on Monday, September 20th. They set a buy rating and a $14.00 price target for the company.

Shares of DNA opened at $10.25 on Wednesday. Ginkgo Bioworks has a 12 month low of $8.90 and a 12 month high of $14.25.

Several large investors have recently bought and sold shares of the company. Sanders Morris Harris LLC bought a new position in shares of Ginkgo Bioworks in the third quarter valued at approximately $2,425,000. Carnegie Capital Asset Management LLC bought a new position in shares of Ginkgo Bioworks in the third quarter valued at approximately $1,518,000. Finally, Foundations Investment Advisors LLC bought a new position in shares of Ginkgo Bioworks in the third quarter valued at approximately $956,000. Institutional investors own 41.15% of the company’s stock.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo Bioworks, formerly known as Soaring Eagle Acquisition Corp., is based in NEW YORK.

Recommended Story: Growth Stocks

Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.